We are looking for a dedicated Director mRNA research who will enlarge and shape Ethris pipeline of delivery technologies, from early proof of concept to a development candidate.
As a highly innovative and growing company in the field of biotechnology, we offer an immensely interesting as well as demanding job in close collaboration with the company management. You will get the opportunity of a “steep learning curve”, quickly growing operational, strategic and personal skills as part of a highly motivated team. An open communication culture and working atmosphere combined with a strong team spirit contribute to our success.
Ethris, based in the biotech hub Planegg/Munich, Germany, is a technical innovator in the field of messenger RNA (mRNA) therapeutics, an emerging alternative to gene therapies and protein-based drugs.
The company has developed two proprietary technology platforms to enable the use of mRNA as a therapeutic agent: stabilized non-immunogenic mRNA (SNIM® RNA) for transcript therapy and lipidoid nanoparticle (LNP) delivery technologies for SNIM® RNA delivery.
We focus on the development of mRNA-based therapeutics and vaccines for the treatment of respiratory diseases. Our technology helps replace or supplement missing or non- functional proteins or introduce new proteins to modulate disease progression or symptoms. We are committed to bringing these new technologies to patients as soon as possible.
Munich is a beautiful city in southern Germany that offers a particularly high quality of life and safety. The Munich area is considered one of the leading biotechnology hubs in Europe. Besides Ethris, the Munich area is home to around 350 companies that are active in the life science sector including roughly 130 small and medium-sized enterprises (SMEs). Most of these SMEs are spin-offs from Munich’s renowned academic institutions: Ludwig Maximilian University, Technical University, Max Planck Institutes of Biochemistry, Neurobiology, and Psychiatry, and the Helmholtz Center for Environmental Health.